Tandem lines up FDA review of new pint-sized insulin pump amid lower-than-expected sales was reported by Andrea Park for FierceBioTech.com, 4 August 2022.
After stumbling a bit in the second quarter of the year, Tandem Diabetes is getting back on its feet, multi-quarter recovery plan already in place. While those three months saw Tandem’s global sales jump 16% compared to last year, reaching a company record of just over $200 million, that wasn’t enough to keep the diabetes tech developer on track toward its 2022 goals. In an earnings report Wednesday afternoon, the company said it would lower its full-year sales forecast to represent growth of between 19% and 20% over 2021, totaling between $835 million and $845 million.
Alongside the lower-than-expected sales, the San Diego-based device maker reported an operating loss of more than $12 million and a net loss of $15.1 million—numbers that had been solidly in the black this time last year.
Chief among the latter category is the Mobi insulin pump. The device is about half the size of Tandem’s flagship t:slim pump and can be fully controlled by a user’s smartphone. It’ll also represent “the first novel form factor launched in our space since we introduced t:slim a decade ago,” CEO John Sheridan said on the call.
Read more: Tandem lines up FDA review of new pint-sized insulin pump amid lower-than-expected sales
Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem was posted on BuisnessWire.com, 3 August 2022.
Senseonics Holdings, Inc. a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System. Anthem’s decision will add more than 45 million covered lives to the long-term implantable CGM system to help manage their diabetes.
This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies that now benefit approximately 250 million covered lives, as well as paying for the healthcare provider’s time for the in-office sensor insertion. This allows Ascensia Diabetes Care, Senseonics’ global commercial partner, to introduce the Eversense CGM System to more people living with diabetes.
Anthem (now Elevance Health) is the second largest health insurance company in the U.S. and a leading health company dedicated to improving lives and communities and making healthcare simpler. Through its affiliated companies, Anthem serves people across 14 states, including more than 45 million within its family of health plans. This most recent coverage decision, in addition to Cigna, Aetna, Humana, HCSC Blue Cross Blue Shield, and other health insurance providers, demonstrates broad-based coverage across the United States from the majority of commercial payers, enabling their members to access the benefits of the long-term Eversense CGM System.
Read more: Senseonics Announces a Positive Coverage Decision for Eversense E3 CGM from Anthem
You should not stay awake after midnight, research reveals — here’s why was written by Deniz Yildiran for InterestingEngineering.com, 5 August 2022.
New research published in Frontiers in Network Physiology puts forward a new hypothesis called ‘Mind After Midnight’, which suggests that the human mind becomes more susceptible to negative thoughts and destructive behavior past midnight if in an alert state.
According to the research, it was already a well-known fact that the loss of sleep, or sleep deprivation involving nocturnal wakefulness, led to cognitive and behavioral dysregulation and how our brains functioned the other day. However, recent findings reveal that changes in cognition and behavior occur when the individual stays awake at midnight.
From an evolutionary perspective, it’s relatable that humans were better hunters during the day than at night. While at night, it was better to get some rest. However, fearing the risk of getting hunted during the night was inevitable, with which scientists associate the increased negative stimuli at night.
“There are millions of people who are awake in the middle of the night, and there’s fairly good evidence that their brain is not functioning as well as it does during the day,” says neurologist Elizabeth Klerman from Harvard University.
Read more: You should not stay awake after midnight
Q2 2022 Diabetes Device Earnings Reports
- Press Release, 4 August 2022: Insulet Reports Second Quarter 2022 Revenue
- Transcript & Audio Recording: Insulet Corporation (PODD) CEO Jim Hollingshead on Q2 2022 Results
TANDEM DIABETES CARE
- Press Release, 3 August 2022: Tandem Diabetes Care Announces Second Quarter 2022 Financial Results
- Transcript & Audio Recording: Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q2 2022 Results
- Press Release, 28 July 2022: Dexcom Reports Second Quarter 2022 Financial Results
- Transcript & Audio Recording: DexCom, Inc.’s (DXCM) CEO Kevin Sayer on Q2 2022 Results
Yes, I saw my Tandem stock was losing ground in the 2nd quarter. Heck, my $100 investment dropped back to $115, from $122 in the quarter. Shoot, I might have been on the line to earn what $123? LOL Tandem will be fine i think